Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
about
Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysisThe clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapyBreast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis.Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotypeAntitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer.Triple-negative breast cancer: role of specific chemotherapy agentsTumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancerPrognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up DataEarly metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.SPHK1 regulates proliferation and survival responses in triple-negative breast cancer.PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data.ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) PatientsClinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancerAnalysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China.Pathological complete response in younger and older breast cancer patientsImpact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer.ALK alteration is a frequent event in aggressive breast cancers.Triple negative breast cancer - prognostic factors and survivalOutcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death.Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review.Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy.Pharmacotherapy of triple-negative breast cancer.A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study.
P2860
Q27001269-26FE3E7F-68A1-465D-9829-AE6F065E4C22Q33378965-C6747508-8C50-45FF-9ED4-01DE85818CF1Q33480671-D416209C-3371-4653-87AD-DF5457BD30DEQ33573055-109EF536-AA33-4E74-BBAF-524CEB30C6BAQ33575459-8B7762B1-A56E-45E9-B3BB-F507037B72A0Q33710233-2BB13C14-2E54-44C4-A245-758D025DC661Q33851448-7B559F4E-23B4-43B1-9BDB-CE8C6C59822FQ33900930-ADE07F24-4F2E-487D-890E-D3E3992643F6Q33986198-31E68237-DAF3-48CE-9B06-3A397DB1B8CBQ33994633-F7B732BD-25DF-46E3-915F-C0555EEC43AAQ34051790-F8D5BBC5-7B17-4F05-9A72-84C7DC276D89Q34227524-4877DD29-78BD-41EE-B107-66275328C873Q34296476-EB495E6F-9B7B-4B0D-B7E6-99E09F6ADC3CQ34328227-B7D26EE8-6AB4-4000-A290-40DBBD9000A5Q34560725-1D8F5045-3481-4647-989F-198AD79C646FQ35051318-8BE82623-2A34-484B-AD9F-68B6393AD845Q35237197-633718B2-0C69-4DF8-B0AC-EF7E77564B0AQ35558914-B82EDD61-D40F-49DF-BB09-492E641EE0BBQ35651216-7B970854-1146-45F8-A5A4-34CD1651B805Q35803370-5E5752FA-E900-45F4-901F-30D6356B67FCQ35909551-4E6A7784-9583-4DFD-94AC-2ABDE411BD8DQ35990463-72FE8716-A941-4B9E-B06C-4111ABD421A0Q36092026-2CA4BC0A-DB35-48AF-ABE8-B2756C281A23Q36105958-AFA3FE72-D2D9-40B4-89D5-7EE4B0067F36Q36177748-59707A95-132D-4430-95F2-417AF0D699CFQ36306513-A59504F7-8F36-49F1-A9CB-43B58E8678E6Q36649503-7E32180C-901D-457B-A0A3-A30F78E0AB4EQ36924445-2A35EF77-481E-42CF-A8D2-3BC474630C52Q37113312-792B11DD-12C5-4418-9453-7FFC073FC25AQ37180350-8554F7D0-602D-474C-A429-B71D1915EB62Q37319292-826CA0BF-8B06-483C-8058-E70F3D3D84F8Q37356185-77A7E964-2452-49F3-B1B8-03895D049E9EQ37547957-E11B46C9-CB30-4828-B727-F5B8E742A8BCQ37565645-0D140941-9C36-429D-829C-65F72D97270BQ37662215-E76F95CA-E1A5-4863-A819-B351F3263331Q37809456-E3B821FD-C8A4-4E1A-9D5A-CF6F033B3BC2Q38047337-F9605386-667F-4BD4-924D-DD9F451276E2Q38420000-7B462CEE-AA8D-4DD7-A914-88EE8760E856Q38451966-D25BC704-6CF5-4088-9FA4-08E945E6C673Q38458792-67DAD0E3-65F7-4E71-B1FD-F86B92103AA9
P2860
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Prognostic impact of clinicopa ...... triple negative breast cancer
@ast
Prognostic impact of clinicopa ...... triple negative breast cancer
@en
Prognostic impact of clinicopa ...... triple negative breast cancer.
@nl
type
label
Prognostic impact of clinicopa ...... triple negative breast cancer
@ast
Prognostic impact of clinicopa ...... triple negative breast cancer
@en
Prognostic impact of clinicopa ...... triple negative breast cancer.
@nl
prefLabel
Prognostic impact of clinicopa ...... triple negative breast cancer
@ast
Prognostic impact of clinicopa ...... triple negative breast cancer
@en
Prognostic impact of clinicopa ...... triple negative breast cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Prognostic impact of clinicopa ...... triple negative breast cancer
@en
P2093
Bhumsuk Keam
Dae Seog Heo
Do-Youn Oh
Dong-Wan Kim
Hee-Jun Kim
In Ae Park
Jee Hyun Kim
Seock-Ah Im
Sung Whan Ha
Tae-You Kim
P2860
P2888
P356
10.1186/1471-2407-7-203
P407
P577
2007-11-01T00:00:00Z
P5875
P6179
1030605683